Regulus Therapeutics Inc. (NASDAQ:RGLS) will post its quarterly earnings results after the market closes on Monday, October 30th. Analysts expect Regulus Therapeutics to post earnings of ($0.19) per share for the quarter.
Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.10). Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.02 million. On average, analysts expect Regulus Therapeutics to post $-0.96 EPS for the current fiscal year and $-0.40 EPS for the next fiscal year.
Regulus Therapeutics Inc. (RGLS) opened at 1.05 on Friday. The firm’s market capitalization is $108.97 million. The firm’s 50-day moving average price is $1.27 and its 200 day moving average price is $1.22. Regulus Therapeutics Inc. has a 1-year low of $0.79 and a 1-year high of $3.38.
ILLEGAL ACTIVITY WARNING: This story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this story on another site, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2017/10/28/regulus-therapeutics-inc-rgls-scheduled-to-post-earnings-on-monday.html.
Several equities analysts have weighed in on the company. Zacks Investment Research raised Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a report on Tuesday, October 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. Chardan Capital cut Regulus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Finally, Wedbush reaffirmed an “ourperform” rating and issued a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday, August 7th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and two have assigned a buy rating to the stock. Regulus Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $3.67.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.